TAO Synergies TAOX
NASDAQ TAOX
$4.07 +0.06 (+1.50%)
As of: Sep 9, 2026 · 11:20 AM EDT

TAO Synergies (TAOX) Non Operating Income (2021 - 2026)

TAO Synergies' (TAOX) quarterly Non Operating Income came in at -$7.7 million in Q2 2026, up 46.62% on a YoY basis from -$5.3 million in Q2 2025, and down 238.72% quarter-over-quarter from $5.6 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Non Operating Income (2021 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Non Operating Income for 6 consecutive years, with -$7.7 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non Operating Income rose 46.62% year-over-year to -$7.7 million; the trailing twelve-month figure through Jun 2026 stood at -$8.8 million (up 57.54% YoY), and the FY2025 full-year result was -$19.7 million, down 230.5% from the prior year.
  • Non Operating Income declined to -$7.7 million in Q2 2026 per TAOX's latest filing, from $5.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $10.4 million in Q4 2022 and bottomed at -$14.5 million in Q2 2025.
  • Historically, Non Operating Income has averaged -$831627.4 across 5 years, with a median of $92608.5 in 2022.
  • The widest YoY moves for Non Operating Income: up 26150.69% in 2023, down 5189.67% in 2023.
  • Over 5 years, Non Operating Income stood at $10.4 million in 2022, then plunged by 89.04% to $1.1 million in 2023, then tumbled by 450.77% to -$4.0 million in 2024, then slipped by 13.91% to -$4.5 million in 2025, then tumbled by 70.23% to -$7.7 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods registered -$7.7 million, $5.6 million, and -$4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Amgen 212.35 Bn 198.36 Bn 7.24 Bn -73.00 Mn
2 Gilead Sciences 181.19 Bn 178.01 Bn 6.22 Bn 387.00 Mn
3 Vertex Pharmaceuticals 132.48 Bn 124.62 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.59 Bn 74.60 Bn 3.93 Bn 234.30 Mn
5 Argenx Se 61.45 Bn 56.27 Bn 1.37 Bn -
6 Moderna 54.89 Bn 49.75 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.21 Bn 30.90 Bn 992.69 Mn -53.64 Mn
8 Biogen 31.38 Bn 30.10 Bn 1.96 Bn -
9 Roivant Sciences 29.81 Bn 29.81 Bn 1.16 Mn -
10 TAO Synergies 30.41 Mn 30.41 Mn - -7.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.73 Mn
Mar 31, 2026 5.57 Mn
Dec 31, 2025 -4.54 Mn
Sep 30, 2025 -2.12 Mn
Jun 30, 2025 -14.48 Mn
Mar 31, 2025 1.45 Mn
Dec 31, 2024 -3.99 Mn
Sep 30, 2024 -3.76 Mn
Jun 30, 2024 307,658.00
Mar 31, 2024 1.48 Mn
Dec 31, 2023 1.14 Mn
Sep 30, 2023 2.19 Mn
Jun 30, 2023 -2.26 Mn
Mar 31, 2023 1.21 Mn
Dec 31, 2022 10.37 Mn
Sep 30, 2022 140,730.00
Jun 30, 2022 44,487.00
Mar 31, 2022 4,610.00
Mar 31, 2021 816.00